Geoepidemiology of autoimmune hemolytic anemia

Autoimmun Rev. 2010 Mar;9(5):A350-4. doi: 10.1016/j.autrev.2009.11.005. Epub 2009 Nov 27.

Abstract

Autoantibodies against red blood cell antigens are considered the diagnostic hallmark of AIHA: Direct antiglobulin test (DAT) completed by cytofluorometry and specific diagnostic monoclonal antibodies (mAbs) allow for a better understanding of autoimmune hemolytic anemia (AIHA) triggers. Once B-cell tolerance checkpoints are bypassed, the patient loses self-tolerance, if the AIHA is not also caused by an possible variety of secondary pathogenic events such as viral, neoplastic and underlying autoimmune entities, such as SLE or post-transplantation drawbacks; treatment of underlying diseases in secondary AIHA guides ways to curative AIHA treatment. The acute phase of AIHA, often lethal in former times, if readily diagnosed, must be treated using plasma exchange, extracorporeal immunoadsorption and/or RBC transfusion with donor RBCs devoid of the auto-antibody target antigen. Genotyping blood groups (www.bloodgen.com) and narrowing down the blood type subspecificities with diagnostic mAbs help to define the triggering autoantigen and to select well compatible donor RBC concentrates, which thus escape recognition by the autoantibodies.

Publication types

  • Review

MeSH terms

  • Anemia, Hemolytic, Autoimmune / diagnosis
  • Anemia, Hemolytic, Autoimmune / epidemiology*
  • Anemia, Hemolytic, Autoimmune / immunology
  • Animals
  • Antibodies / immunology
  • Antibodies, Monoclonal / immunology
  • Autoantibodies / blood
  • Autoantibodies / immunology
  • Autoantigens / immunology
  • B-Lymphocytes / immunology
  • Blood Platelets / immunology
  • Coombs Test
  • Erythrocyte Transfusion / adverse effects
  • Erythrocytes / immunology
  • Humans
  • Immune Tolerance / immunology
  • Mice
  • Plasma Exchange / adverse effects
  • Transfusion Reaction

Substances

  • Antibodies
  • Antibodies, Monoclonal
  • Autoantibodies
  • Autoantigens